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     The neuronal α7 nicotinic receptor subunit 
gene (CHRNA7) is partially duplicated in 
human genome forming a hybrid gene 
(CHRFAM7A) with the novel FAM7A gene. 
The hybrid gene transcript, dupα7, has been 
identified in brain, immune cells and the   
HL-60 cell line, although its translation and 
function are still unknown. In this paper 
dupα7 cDNA has been cloned and expressed 
in GH4C1 cells and Xenopus oocytes to study 
the pattern and functional role of the 
expressed protein. Our results reveal that 
dupα7 transcript was natively translated in 
HL-60 cells and heterologously expressed in 
GH4C1 cells and oocytes. Injection of dupα7 
mRNA into oocytes failed to generate 
functional receptors, but, when co-injected 
with α7 mRNA, at α7/dupα7 ratios of 5:1, 
2:1, 1:1, 1:5 and 1:10, it reduced the nicotine-
elicited α7 current generated in control 
oocytes (α7 alone) by 26%, 53%, 75%, 93% 
and 94%, respectively. This effect is mainly 
due to a reduction in the number of functional 
α7 receptors reaching the oocyte membrane, 
as deduced from α-bungarotoxin binding and 
fluorescent confocal assays. Two additional 
findings open the possibility that the 
dominant-negative effect of dupα7 on α7 
receptor activity observed in vitro could be 
extrapolated to in vivo situations: (i) 
compared with α7 mRNA, basal dupα7 
mRNA levels are substantial in human 
cerebral cortex and higher in macrophages; 
and (ii) dupα7 mRNA levels in macrophages 
are down-regulated by IL-1β, LPS and 
nicotine. Thus, dupα7 could modulate α7 
receptor-mediated synaptic transmission and 
cholinergic anti-inflammatory response.  
____________________________________
  
     Neuronal α7 nicotinic acetylcholine receptors 
(α7 nAChRs) are widely expressed in the central 
and peripheral nervous systems. In neurons, 
homomeric α7 nAChRs, composed of five α7 
subunits, modulate neurotransmitter release in 
presynaptic nerve terminals and induce 
excitatory impulses in postsynaptic neurons (1-
4). Signaling through α7 nAChRs in the central 
nervous system has been associated with 
neuronal plasticity and cell survival (5-7), while 
impaired activity of this receptor has been 
implicated in the pathogenesis of schizophrenia, 
Alzheimer´s disease and depression (8-12). The 
presence of α7 nAChRs has also been reported 
in non-neuronal cells such as vascular and brain 
endothelial cells, bronchial epithelial cells, 
keratinocytes, astrocytes, synoviocytes, 
thymocytes, lymphocytes, bone marrow cells, 
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monocytes, macrophages, microglia and 
astrocytes [see (13) and the references therein]. 
Interestingly, the α7 nAChR expressed in 
macrophages (and probably in other immune 
cells) is essential for vagus nerve regulation of 
acute pro-inflammatory cytokine release during 
systemic inflammatory response [see (14) and 
references therein]. The α7 nAChR is a target 
for natural and synthetic ligands; however, little 
is known about endogenous receptor-regulating 
molecules. 
     The α7 nicotinic subunit encoded by gene 
CHRNA7 is located on the long arm of 
chromosome 15(15q13-q14). A hybrid gene 
(CHRFAM7A) resulting from a fusion of a 
partial duplication of CHRNA7 with FAM7A 
gene was identified at 1.6 Mb from CHRNA7 
toward the centromeric region (15-16). CHRNA7 
and CHRFAM7A are highly homologous (> 
99%) from exon 5 until the 3’-UTR region. In 
contrast, the hybrid has replaced exons 1-4 of the 
original CHRNA7 with the exons D, C, B, A of 
FAM7A, inserted in an Alu sequence of intron 4 
of CHRNA7, 700 bp upstream from exon 5. 
Moreover, CHRFAM7A is polymorphic with a 
few rare individuals who completely lack a copy 
of the gene. Most people (> 95%) have one or 
two CHRFAM7A copies and, in some cases, 
there is a 2 bp deletion in exon 6 (16-17). The 
acquisition of this duplication seems to be a 
recent evolutionary event since CHRFAM7A 
only appears in humans but not in other higher 
primates (18). The above findings would 
indicate that the hybrid gene could confer an 
evolutionary advantage on the genotype with the 
duplication.  
     To date, the possible functional significance 
of this CHRNA7 duplication is unknown, 
although there are conflicting reports in the 
literature suggesting an association between 
CHRFAM7A polymorphisms and certain 
psychiatric and neurological disorders, such as 
schizophrenia, bipolar depression, Alzheimer´s 
disease, dementia with Lewy bodies or Pick’s 
disease (19-24). The CHRFAM7A transcript, 
dupα7, has been identified in hippocampus, 
cortex, corpus callosum, thalamus, putamen, 
caudate nucleus and cerebellum (15, 25-26) and 
in peripheral blood mononuclear cells (PBMC), 
lymphocytes, synoviocytes as well as HL-60 
cells (25-28). Despite its wide distribution, to 
date there are no experimental evidences 
demonstrating that this transcript is translated 
and what the possible functional role of the 
resulting protein might be. 
     This particular paper seeks to shed some 
light on the last two questions. Using GH4C1 
cells and oocytes, we have studied the function 
of heterologously expressed dupα7 protein 
while, to study the native transcript, we use HL-
60 cells, human CTX and human macrophages. 
A set of experimental approaches, including 
molecular biology and confocal images of 
labeled receptors, combined with 
pharmacological and electrophysiological 





     Cell Lines and Oocytes⎯ The rat pituitary-
derived GH4C1 cells were grown in DMEM  
containing 10% fetal calf serum, the human 
acute promyeloid leukemic HL-60 cell line in 
RPMI 1640 medium supplemented with 10% 
fetal bovine serum. In both cases, 100 units.ml-1 
of penicillin G sodium and 100 µg·ml-1 of 
streptomycin sulfate were added. Both cell types 
were maintained at a density of 1x106 to 2x106 
cells/ml at 37 ºC in a humidified 5% CO2 
atmosphere. Mature female X. laevis frogs were 
obtained from a commercial supplier (Xenopus 
Express, Haute-Loire, France). Techniques for 
oocyte isolation have been described by our 
group elsewhere (29-32).  
     Isolation of Human Monocytes and 
Differentiation to Macrophages ⎯ The PBMCs 
were isolated from blood buffy coats from 
healthy individual donors and then, the 
monocyte-enriched cell population was purified 
from PBMC by a double density-gradient 
protocol as previosly described (33). Monocytes 
were collected, washed, resuspended in complete 
RPMI 1640 medium and seeded either onto 
coverslips in 24-well tissue culture plates (5x105 
cells per well) or onto 60 mm Petri dishes (106 
cells·ml-1). Cells were allowed to diferentiate to 
macrophages (MØ) for 7-9 days in the presence 
of macrophage colony stimulating factor 
(MCSF; 2 ng· ml-1) in complete culture medium.  
     Cloning of dupα7 cDNA ⎯  Dupα7 was 
cloned in two steps, using either human thalamus 
(for the 3’ region) or MØ (for the 5’ region) 
RNAs. After first strand cDNA synthesis with 
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M-MLV reverse transcriptase (Gibco/BRL), the 
3’-region was amplified with primers: A7S4 (5´-
CACACACGTCTCGCCCTCGCCCTGCTG-
GT-3´); and A7AS4 (5´-CACCCCCAAATCTC-
GCCAA-3´). We amplified the 5’-region with 
primers: DUPA7S              (5´-TGACAATCCA-
AAGGTGCACA-3´) and A7AS3 (5´-
CACACACGTCTCGAGGGCGGAGATGAG-
CA-3´). Both fragments were cloned in pMOS-
Blue. To obtain the whole coding sequence, the 
3’-region fragment was digested with BsmBI 
(underlined in primers A7S4 and A7AS3) and 
SacI and ligated to the vector containing the 5’-
region, digested with the same enzymes. The 
complete cDNA was transferred directly from 
dupα7·pMOS-Blue to pcDNA3 (digested with 
XbaI and BamHI). For oocyte injection 
experiments, dupα7 was amplified from 
dupα7·pMOS-Blue with DupSpeI(S) 5´-
ACTAGTGCCACCATGCAAAAATATTGCA
TCTACC-3´ and DupNotI(AS) 5´-
GCGGCCGCCGTGGTTACGCAAAGTCTTTG
G-3´ (with the recognition sequences for SpeI 
and NotI underlined, respectively) and cloned 
into pSP64T digested with the same enzymes.  
     Preparation of RNAs ⎯ Techniques for RNA 
isolation from cells and tissues and in vitro 
transcription mRNA synthesis have been 
described elsewhere (31-32). Plasmids 
dupα7·pSP64T, α7·pSP64T and 
RIC3·pGEMH19 were linearized with BamHI, 
Xba and NheI, respectively, and then in vitro-
transcribed with SP6 (dupα7, α7) or T7 (RIC3) 
polymerases using the mMACHINE kit from 
AMBION (Austin, TX, USA). Messenger RNA 
was dissolved in RNAse-free water (1μg/μl) and 
aliquots stored at –80ºC until use.  
 Immunofluorescent Staining and Confocal 
Microscopy⎯ GH4C1 cells were electroporated 
with plasmids dupα7·pcDNA3, α7·pcDNA3 or 
pcDNA3. Then, they were plated on 12-mm 
glass coverslips for 48 h before processing. Cells 
were fixed with 4% paraformaldehyde, 
permeabilized with 0.25% Triton X-100 and 
stained overnight with the monoclonal anti-α7 
subunit antibody (Mab 306, Sigma-Aldrich, 
1:3000) in PBS with 5% normal goat serum 
(NGS) at 4ºC, followed by incubation with 
AlexaFluor 488 goat anti-mouse IgG (1:400) for 
2h at room temperature. All images were 
captured with a Leica TCS SP2 Spectral 
confocal laser scanning microscope as reported 
previously (31-32). Fluorescence intensity, 
expressed as arbitrary units (a.u.), was measured 
in a narrow region of interest (ROI) located 
between the plasma membrane and the cell 
nucleus. In other cases, fluorescence intensity 
was measured along the X-axis of the entire cell 
body.  
     Techniques for mRNA injection and 
immunodetection of foreign proteins expressed 
in intact injected oocytes have been described 
elsewhere (31-32). Five days after injection, 
protein expression was analyzed using the same 
antibodies and dilutions as for GH4C1 cells. 
Oocytes were mounted in glycerol/buffer (70:30) 
under a glass coverslip on a glass dual-well 
slide. The slide was fastened upside down on the 
stage of the Leica confocal microscope and 
visualized with a 20X lens. The fluorescent 
signal was determined as a.u. in an ROI located 
on the animal surface of the oocyte. 
     α-Bungarotoxin Staining and Confocal 
Microscopy ⎯ Native expression levels of 
functional α7 nAChRs in MØ were analyzed 
using fluorescein isothiocyanate-labeled α-
bungarotoxin (FITC-αBgtx) and confocal 
microscopy. Cells were incubated with FITC-
αBgtx (3 μg· ml-1; Sigma) as previously 
described (34). Cells from the same culture 
incubated with nicotine (500 μM) or αBgtx(1 
μM), before and during the addition of FITC-
αBgtx, were used as a negative control. After 
several rinses, MØ were 4% paraformaldehyde-
fixed, washed and mounted on coverslips. 
Heterologous expression of functional α7 
nAChRs in mRNA-injected oocytes was 
analyzed 5 days after injection by incubation 
with FITC-αBgtx (3 μg·ml-1) in Barth’s solution, 
as has been described for MØ. Oocytes were 
rinsed, fixed in 4% paraformaldehyde, mounted 
in glycerol/buffer (70:30), and visualized by 
confocal microscopy. Fluorescent signal was 
determined as described elsewhere (31-32).  
     Electrophysiological Recordings and Surface 
Receptor Binding Assay ⎯ Electrophysiological 
recordings of foreign proteins expressed in 
oocytes have been described in detail by our 
group elsewhere (29, 32, 35). The agonist 
concentration eliciting half-maximal current 
(EC50) and the Hill coefficient values were 
estimated through nonlinear regresion analysis 
using the four-parameter logistic equation of the 
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GraphPad Prism sofware. Total surface 
expression of αBgtx binding sites on the surface 
of mRNA-injected oocytes was assayed with 
[125I]α-Bgtx (Amersham Pharmacia Biotech, 
Little Chalfont, UK), as described elsewhere 
(36). Briefly, five days after injection, oocytes 
placed on 24-well plates were preincubated 
during 15 min with Ringer’s solution containing 
fetal calf serum (6%). Then they were incubated 
for 2 h at 18ºC in a final volume of 300 µl of the 
above solution containing increasing 
concentrations (1-10 nM) of [125I]α-Bgtx. After 
incubation, labeled medium was removed and 
oocytes washed several times with Ringer's 
solution before counting total bound 
radioactivity in a Beckman Coulter γ counter. 
Nonspecific binding was determined in non-
injected oocytes incubated under the same 
conditions; this value was subtracted from total 
binding to yield specific binding.  
     Northern Blot Analysis ⎯ Poly(A)+ RNAs (4 
µg/lane) isolated from human CTX and from 
HL-60 cells were separated by 1% 
formaldehyde/agarose gel electrophoresis, 
transferred onto a nylon blotting membrane 
(Schleicher & Schuell, Dassel, Germany) and 
hybridized at 68ºC overnight with the 32P-labeled 
probe (781 bp) obtained by digestion of 
dupα7·pMOS-Blue with SpeI and SmaI. The 
resulting fragment starts in the ATG of exon B 
and extends to the 51 nucleotide of exon 10; 
thus, it recognizes the dupα7 and α7 transcripts.  
     Isolation of Polysome-Bound mRNA and 
Real-Time Quantitative PCR (Q-PCR)  ⎯ 
Polysome-bound mRNA from HL-60 cells was 
obtained as described by Del Prete and 
coworkers (37), except that cells were pretreated 
with 0.1 mg·ml-1 cycloheximide for 10 min at 
37ºC. In the conditions used, ribonucleoprotein 
particles, isolated ribosomal subunits and 
monosomes remain in fractions 1-10 (from the 
top) while polysomes are recovered in fractions 
11-20. After this, monosomic and polysome 
fractions were regrouped into two pools and one 
aliquot (10 μl, diluted to 100 ng·μl-1) from each 
pool was used for Q-PCR mRNA quantification. 
We added 10 ng of in vitro transcribed luciferase 
mRNA (from pGL3-control plasmid) to each 
aliquot as an endogenous marker for 
quantification . The level of gene expression in 
human CTX and human MØ was also assessed 
by Q-PCR for reverse transcribed mRNA or total 
RNA, respectively.  A combination of Taq-Man 
and SYBR green-based assays for amplicon 
detection on the ABI Prism 7900 device was 
used. The following primers were used: for 
dupα7, forward 5´-CAATTGCTAAT-
CCAGCATTTGT-3´ (position 603-624 of 
sequence in NM_139320) and reverse 5´-CC-
CAGAAGAATTCACCAACACG-3´ (position 
704-683 in NM_139320); for α7, 
Hs_CHRNA7_2_SG, Quantitec Primer Assay, 
QT01681211 (Qiagen); for TBP (encoding for 
the TATA binding protein), forward 5´-
CGGTTTGCTGCGGTAATCA-3´ and reverse 
5´-TGTTGGTGGGTGAGCACAAG-3´;  for 
luciferase, forward 5´-TGGAAGA-
CGCCAAAAACATAAAG-3´ and reverse 5´-
AGCAATTGTTCCAGGAACCAGGGC-3´. For 
dupα7 and α7 mRNA quantification in MØ, 
TaqMan Hs00415199_m1 and Hs01063372_m1 
(Applied Biosystems) were respectively used. 
Analysis of the melting curves demonstrated that 
each pair of primers amplified a single product. 
Q-PCR reaction for each mRNA was performed 
in triplicate and all results normalized to the 
expression of 18S rRNA (Ambion primers). 
Relative gene expression values were calculated 
by the comparative delta Ct method using the 
Sequence Detection System 1.2 software 
(Applied Biosystems). 
     Chemicals⎯ Unless otherwise indicated, all 
products were purchased from SIGMA (Madrid, 
Spain). AlexaFluor 488 goat anti-mouse IgG was 
from Molecular Probes (Eugene, OR, USA) and 
DMEM and RPMI media from Gibco 
(Invitrogen, UK). The human recombinant IL-1β 
was purchased from Peprotech (London, UK) 
and PNU120596 from Tocris Bioscience 
(Bristol, UK).  
 
RESULTS 
   
     Analysis of the dupα7 Coding Sequence⎯ 
The cloned full-length dupα7 cDNA codes for a 
1236 nucleotide sequence similar to the one 
previously deposited in NCBI and which 
corresponded to the dupα7 isoform 1 (accession 
number NM_139320), with minimal variations. 
Our sequence contains two neutral transitions: 
C/T and A/G at positions 654 and 986, 
respectively, but it retains the two TG 
nucleotides at positions 497-498 on exon 6. 
Using the ConPred II software for 
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transmembrane topology prediction, one can 
observe that the resulting 412 aa. polypeptide 
preserves many of the distinctive features of the 
nAChR subunits, with the N- and C-terminals 
outside the membrane and the four 
transmembrane domains (M1-M4) as well as the 
long intracellular loop between M3 and M4 (Fig. 
2A). However, as has been reported previously 
(15), dupα7 protein does lose a substantial part 
of the long N-terminal domain of α7 and thus 
lacks the recognition sites for ACh and α-Bgtx.  
     Heterologous Expression of dupα7 versus 
α7⎯ Expression of foreign proteins was 
analyzed in GH4C1 cells transfected with 
plasmids dupα7·pcDNA3 or α7·pcDNA3 and in 
oocytes injected with dupα7 and α7 mRNAs. 
The GH4C1 cell line was selected for two 
reasons: 1) it does not express dupα7 or α7, 
making visualization of foreign protein 
expression feasible; and 2) it expresses the RIC-
3 chaperone (38) making it an excellent model to 
express functional α7 nAChRs. The confocal 
images obtained in transfected GH4C1 cells 
stained with Mab306 show a high expression 
level of both proteins, in contrast to low 
fluorescence detected in the negative control 
cells transfected with pcDNA3 (Fig. 1, A and C). 
The analysis of the protein expression along the 
X axis of the cell reveals two expression peaks 
located in the cell periphery; the α7 peak seems 
to be located more externally than the dupα7 
peak (Fig. 1 B).  
     Non-injected oocytes (control) have low basal 
fluorescence, which increases markedly at or 
near the cell surface of the animal hemisphere in 
dupα7 or α7 mRNA-injected oocytes incubated 
with the above antibody (Fig. 2B). Nevertheless, 
the fluorescence signal corresponding to dupα7 
is significantly lower (33 ± 7%, n = 7; p≤0.05) 
than that found in α7 mRNA-injected oocytes. 
As has been reported previously, no intracellular 
fluorescence was observed in mRNA-injected 
oocytes under any experimental condition (39). 
This may be due to: 1) the inability of the laser 
to penetrate far into a large 1 mm cell; 2) the 
quenching of the fluorescent signal by the oocyte 
yolk/pigment; or 3) the possibility that 
intracellular antibody distribution may be too 
diffuse to be detected.  
     Dominant Negative Effect of dupα7 on α7 
Currents Expressed in Oocytes ⎯ Once the 
heterologous expression of the dupα7 protein in 
GH4C1 cells and oocytes was confirmed, we 
proceeded to study its possible functional role in 
the latter cell type. The study began with the 
electrophysiological recording of ACh-elicited 
currents [IACh] in oocytes injected with α7 
mRNA (2.5 ng/oocyte). In all experiments RIC3 
mRNA (2.5 ng) was co-injected with α7 mRNA 
since this treatment almost doubles the 
amplitude and reproducibility of the recorded 
currents.  Repeated pulses of ACh (100 μM, 1s) 
or nicotine (30 μM, 1s) at 1 min intervals, 
applied to oocytes injected with increasing 
concentrations of dupα7 mRNA (from 0.5 to 25 
ng/oocyte), failed to produce any response (not 
shown). In contrast, co-injection of dupα7 with 
α7 mRNA (2.5 ng) resulted in a concentration-
dependent reduction of α7 current induced by 
nicotine, INic (Fig. 3, A and B). The co-injection 
of 0.5 ng/oocyte of dupα7 mRNA (α7:dupα7 
ratio of 5:1) was sufficient to reduce 
significantly (26 ± 8%, n= 6; p≤ 0.01) the 
amplitude of INic and this blockade exceeded 
90% when the α7:dupα7 ratio was 1:5 or 1:10.  
     The next experiments were designed to 
analyze the nature of the dominant negative 
effect of dupα7 on the α7 current. One 
possibility is that dupα7 is integrated into the 
pentameric structure of the expressed receptor, 
changing its pharmacological properties. 
Another possibility is that dupα7 interferes with 
the proper assembly of α7 subunits that form 
mature homopentameric α7 nAChR, which is 
essential for receptor trafficking from 
endoplasmic reticulum (ER) to the cell 
membrane. The following experiments sought to 
explore both possibilities.  
     Dupα7 Reduces α7 Current Amplitude but 
not Receptor Response to ACh ⎯ Figure 3 (C 
and D) shows the concentration-response curves 
to ACh in oocytes injected with 2.5 ng of α7 
mRNA and the corresponding amount of dupα7 
mRNA according to the indicated  α7:dupα7 
ratio. Each oocyte was stimulated with 
successive pulses of increasing concentrations of 
agonist and, at the end of experiment, with a 
control pulse of 1 mM ACh that induced the 
maximum current [Imax]. Figure 3C shows the 
original traces of IACh obtained in one α7 
mRNA-injected oocyte stimulated as described 
above. As expected, for a given ACh 
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concentration, the higher the proportion of 
dupα7 in the mixture of injected mRNA, the 
lower the IACh. Thus, the Imax for the 
combinations 1:0, 2:1, 1:1 and 1:5 of α7: dupα7 
was 8.4 ± 1.5 μA, 3.9 ± 0.7 μA, 2.1 ± 0.5 μA and 
0.6 ± 0.2 μA, respectively. The currents induced 
by each of the ACh concentrations tested in the 
oocyte were normalized to the Imax. Figure 3D 
shows pooled results of normalized currents 
obtained in several oocytes (n = 5-6) assayed for 
each condition; each value represents mean ± 
SEM. The EC50 and Hill coefficient values are 
shown in the table below; the analysis of 
variance (ANOVA) applied to both parameters 
showed no significant differences between the 
four groups of oocytes.  
     Dup α7 Reduces the Number of Functional 
α7 nAChRs in the Oocyte Membrane⎯  To 
examine whether the dupα7 effect was due to a 
reduction in the number of functional α7 
nAChRs incorporated into the surface of the 
oocyte, we incubated the oocytes with either the 
Mab306 antibody, which detects both α7 and 
dupα7, or with FITC-αBgtx, which binds to the 
extracellular N-terminal region present in the α7 
subunit alone. Three groups of mRNA-injected 
oocytes (α7, dupα7 or 1:1 α7:dupα7), along 
with a fourth group without an injection 
(control) were analyzed. The confocal images in 
Figure 4A show the fluorescent signal detected 
in eight typical intact oocytes from the same 
donor subjected to one or the other staining 
process. Figure 4B shows the average 
fluorescence values, expressed as a percentage of 
the control, determined in several oocytes (n = 5-
8) used for testing each experimental condition. 
While the antibody detected a robust expression 
of α7 nAChRs and a small fluorescent signal 
generated by dupα7 in oocytes injected with one 
or the other mRNA, FITC-αBgtx only detected 
the expression of the first protein. However, 
regardless of the staining technique used, the co-
injection of dupα7 with α7 mRNA significantly 
reduced the expression of α7 nAChRs on the 
surface of the oocyte. In fact, in oocytes labeled 
with FITC-αBgtx, the α7 signal was reduced (≈ 
70%) to levels that were indistinguishable from 
those in the control. It should be noted that, 
regardless of the staining process used, confocal 
images show a polarized distribution of nicotinic 
subunits on the animal membrane of the oocyte. 
 Coexpression of dupα7 with α7 Reduces the 
Number of [125I]α-Bgtx Binding Sites on the 
Oocyte Surface ⎯Two groups of oocytes 
injected with α7 mRNA (control) or with the 
combination 1:4 of α7:dupα7 mRNA were 
incubated with increasing concentrations of 
[125I]α-Bgtx as described in “Experimental 
Procedures”. Compared to controls, the injection 
of dupα7 mRNA reduced markedly and 
significantly the maximum specific binding of 
radioligand (Bmax), from 8,277±331 to 4,552± 
288 cpm; p≤ 0.01 (Fig. 4C, bottom). 
Additionally, the equilibrium dissociation 
constant (Kd) suffered a slight but significant 
increase in the presence of dupα7 (from 
1.37±0.17 to 4.28±0.56 nM; p≤ 0.05).  
     Effect of Positive Allosteric Modulators on 
IACh Expressed in Oocytes Injected with Several 
Combinations of α7:dupα7 mRNA⎯The 
following experiments were designed to look for 
possible pharmacological differences among 
oocytes injected with different α7:dupα7 mRNA 
ratios. We used two positive allosteric 
modulators (PAMs) of α7 nAChRs, each one 
representative of one of the two available 
allosteric groups. Group-I includes agents like 5-
hydroxyindole (5HI), which potentiates the peak 
agonist-evoked response mediated by α7 
nAChR, but it does not modify the duration of 
the response (40). Meanwhile, PNU120596,   
representative of Group-II, increases the peak 
agonist-evoked response and markedly prolongs 
the macroscopic currents in the presence of 
agonist, possibly by interfering with the 
desensitization process (41). The different 
effects of these two groups of PAMs indicate the 
existence of distinct allosteric binding sites with 
specificity for either 5HI or PNU120596.  
     The effects of 5HI on IACh were analyzed in 
several groups of oocytes injected with different 
combinations of α7: dupα7 mRNA, using the 
group of α7 mRNA-injected oocytes as 
reference (Fig. 5, upper left). The oocytes were 
stimulated with successive pulses of ACh (30 
μM, 1s), applied at intervals of 1 min. Once the 
IACh was stable (control), we incubated the 
oocytes with 3 mM 5HI (30s before and during 
the ACh pulse), evaluating its enhancing effect 
on control IACh. Figure 5 (A, B) shows that 5HI 
increased the amplitude of control IACh about 5-
fold and that this effect was not significantly 
different in any oocyte group. Additionally, 5HI 
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did not alter the kinetics of IACh in any of the 
oocyte groups as can be deduced after 
normalization of the original traces obtained in 
two oocytes injected with either α7 or α7:dupα7 
(1:1) mRNAs (Fig. 5A, inset).  
     A different design was used to evaluate the 
effect of PNU120596 in oocytes injected with 
several combinations of α7:dupα7 mRNA (Fig. 
5, top right). The α7 mRNA-injected group was 
used as reference. The oocytes were stimulated 
with successive pulses of ACh (30 μM, 1s, at 1 
min intervals). Once IACh was stabilized 
(control), we perfused 300 nM PNU120596 
before and during the ACh pulse, evaluating its 
enhancing effect on control IACh. Since there was 
a progressive positive effect of the modulator on 
IACh over successive ACh pulses, we evaluated 
this effect over six consecutive agonist pulses. 
Figure 5 (C, D) shows that the higher the 
proportion of dupα7 in the mixture of injected 
mRNA, the lower the enhancing effect of 
PNU120596 on peak IACh. Normalization of the 
currents (Fig. 5C, inset) shows that the allosteric 
modulator delays desensitization of IACh in all the 
oocyte groups, with no significant differences, 
probably because of the shortness of the ACh 
pulse.  
     Identification of the dupα7 Transcript in 
Cerebral Cortex and HL-60 Cells⎯Although 
the presence of the dupα7 transcript has been 
detected in different brain areas, immune cell 
types and the HL-60 cell line by PCR, the size of 
this mRNA is unknown. Northern blot analysis 
was performed with mRNAs extracted from 
human CTX and HL-60 cells since the latter cell 
type mainly expresses dupα7 and not α7 (25). 
Figure 6A shows a well-defined band of ≈ 3.9 kb 
in HL-60 cells, also present in CTX, the latter 
also containing bands of 5.8, 3.3, 2.1 and 1.4 kb.  
     Dupα7 mRNA is Translated in HL-60 Cells⎯ 
Antibodies that specifically differentiate α7 and 
dupα7 are not available, so it is still impossible 
to demonstrate the existence of dupα7 protein in 
vitro or in vivo. To solve this difficulty we have 
gone a step backwards in the translation process 
and used an indirect approach, one that looks for 
dupα7 mRNA in the polysomal fraction since 
we know that polysome-bound mRNAs are 
being translated (42, 43). After sucrose gradient 
centrifugation of an HL-60 cell extract as 
described in “Experimental Procedures”, a 
bioanalysis assay for each fraction showed that 
tRNA appears in fractions 1-4, the migration 
peak for the small 40S ribosomal subunit (18S 
peak) is in fractions 5-6, followed by the 
migration peak for the large 60S ribosomal 
subunit (28S peak) in fractions 7-10, while 
fractions 11-20 contain the polysomal fraction 
(28S and 18S). All fractions were regrouped into 
two pools (monosomal and polysomal) as 
described in “Experimental Procedures”. 
Relative expression of dupα7, TBP and 
luciferase mRNAs was quantified in the two 
pools. TBP mRNA was used as the positive 
control since it is constitutively translated in all 
cell types and, therefore, must be present in the 
“polysomal fraction” of HL-60 cells. Figure 6B 
shows the relative levels of TBP mRNA and 
dupα7 mRNA in monosomal and polysomal 
pools, expressed as a percentage of the total 
mRNA in both fractions. The results reveal that, 
as expected, the TBP transcript was in the heavy 
sucrose fractions (polysomes), as was the dupα7 
transcript.  
     Levels of the dupα7 Transcript in Human 
Cerebral Cortex and Macrophages and its 
Modulation by Different Treatments ⎯We 
performed Q-PCR experiments to determine 
levels of dupα7 and α7 mRNAs in CTX and 
MØ. The PCR reaction was performed with 
human CTX mRNA or with total RNA from 
cultured human MØ using the primers listed in 
“Experimental Procedures”. The results in 
Figure 7A show that dupα7 expression is around 
22% of the α7 expression in CTX. The opposite 
happens in MØ, where the α7 mRNA levels are 
approximately 7% of those of dupα7. Despite 
this low level of α7 mRNA in relation to dupα7 
in MØ, these cells clearly show the expression of 
functional α7 nAChRs, as reflected by confocal 
images of MØ in FITC-αBgtx labeled cultures 
(Fig. 7B, left). The receptor specificity of this 
staining is demonstrated by the disappearance of 
the fluorescent signal in cells preincubated with 
1μM αBgtx or 500 µM nicotine (Fig. 7B, right). 
Finally, MØ in culture were subjected to 
different treatments to evaluate if dupα7 mRNA 
levels could be modulated. Figure 7C shows that 
the pro-inflammatory cytokine interleukin-1β 
(IL-1β), LPS from Salmonella abortus and 
nicotine, all markedly and significantly reduced 









     In this study we have cloned and expressed, 
for the first time, the full-length coding sequence 
of dupα7 in GH4C1 cells and oocytes. 
Additionally, we have performed a functional 
study of the protein expressed in the latter cell 
type. Our results indicate that dupα7 acted as a 
dominant negative regulator of α7 nAChR 
activity through a mechanism involving 
reduction in the number of functional α7 
nAChRs incorporated into the oocyte surface. 
Determining whether the dupα7 subunit plays a 
functional role in vivo, wherever it is co-
expressed with α7, requires additional 
experiments but our preliminary results obtained 
in human cerebral cortex, human macrophages 
and HL-60 cells suggest this possibility. Here we 
discuss the most relevant results of the present 
study. 
     The parallel confocal analysis of dupα7 and 
α7 protein expression in transfected GH4C1 
cells and in mRNA-injected oocytes labeled with 
the Mab306 antibody indicates that the two cell 
types express both foreign proteins, although 
their patterns and expression levels differ. Thus, 
GH4C1 cells show a similar high α7 and dupα7 
expression (Fig. 1, A and C), although a careful 
analysis of the α7 expression along the X axis of 
the cell reveals a peak localized in the cell 
membrane while the dupα7 expression peak 
seems to have an inner location, probably within 
the ER (Fig. 1B). Meanwhile, expression levels 
of dupα7 on the cell surface of mRNA-injected 
oocytes represent only one third of that of the α7 
subunit (Fig. 2B), making it likely that most of 
the synthesized dupα7 proteins in oocytes are 
retained in the ER. However, our data do not 
preclude the possibility that a small fraction of 
dupα7 can form homo- or heteropentameric 
structures with other nAChR subunits able to 
migrate to the cell membrane.  
     Despite the low expression of dupα7 
compared to α7 in the oocyte surface, there is no 
doubt that the first protein clearly interferes with 
the second. This assertion is deduced from 
electrophysiological records of INic obtained in 
oocytes injected with different combinations of 
α7:dupα7 mRNA (Fig. 3, A and B). Thus, 
although dupα7 subunits are not capable of 
forming, by themselves, homomeric nAChRs 
activated by ACh or nicotine (not shown), they 
do produce a concentration-dependent dominant 
negative regulatory effect on α7 current. The 
question that now arises is to identify the 
mechanism through which dupα7 exerts this 
effect. The following hypotheses, individually or 
in combination, could provide an answer. Thus, 
dupα7 could: 1) act at the transcriptional level of 
CHRNA7; 2) interfere with the proper 
oligomerization and assembly of α7 subunits in 
the ER, decreasing the number of mature α7 
nAChRs able to migrate to the oocyte 
membrane; and/or 3) be integrated into a 
putative “α7/dupα7 heteromeric receptor” 
whose affinity or gating mechanism would be 
affected by the incorporation of the atypical 
subunit. 
     The first proposal can be ruled out, at least in 
terms of the dominant negative effect of dupα7 
on α7 nAChRs in oocytes because, in this case, 
the injected mRNAs are obtained by in vitro 
transcription from the corresponding cDNAs. 
Although our results cannot rule out the 
possibility that dupα7 might produce some kind 
of interference in vivo at the transcriptional level 
of CHRNA7, this is unlikely since native 
transcripts that effectively regulate gene 
expression are “antisense” (44) and the 
orientation of the dupα7 transcript in human 
brain is in the “sense” direction of transcription 
(26).  
 Collectively, our data tend to support the 
second hypothesis since dupα7 coexpression 
significantly reduces the number of α7 nAChRs 
expressed on the oocyte surface, as can be 
inferred by the drastic decrease of fluorescent 
signal in Mab306-incubated oocytes as well as 
by the reduction of the Bmax in [125I]α-Bgtx 
binding assays (Fig. 4). This hypothesis is 
further reinforced by the similar degree of 
reduction of both INic (≈ 74%) and α7 nAChR 
expression (≈ 70%) in FITC-αBgtx labeled 
oocytes injected with equimolar amount of α7 
and dupα7 mRNAs (Figs. 3B and 4B-right).  
 In relation to the third hypothesis, two of 
our findings seem to support this alternative in 
combination with the second proposal raised 
above. On the one hand, there was a small but 
statistically significant increase of Kd in oocytes 
co-injected with the combination 1:4 of 
α7:dupα7 mRNA compared to those injected 
8 
 
Dominant negative effect of dupα7 on α7 receptor activity 
 
 
with α7 mRNA alone (Figure 4C, bottom). Since 
Kd is the reciprocal of affinity, the higher the 
Kd, the lower the affinity of the receptor 
expressed by Bgtx. On the other hand, there was 
a different behavior of PNU120596 and 5HI in 
relation to their ability to enhance IACh in oocytes 
injected with different combinations of 
α7:dupα7 mRNA (Fig. 5). While the former 
drug distinguishes between different groups of 
oocytes, the second does not. These results can 
be interpreted in light of different α7 modulation 
sites required by one or the other PAM, because 
PNU120596 interacts with transmembrane 
domains while 5HI requires the extracellular N-
terminal domain of the α7 subunit (40, 45, 46). 
Thus, PNU120596 could act on homo- and 
heteromeric receptors, while 5HI would do so 
only on homomeric α7 nAChRs. 
 Northern blot analysis shows a band of a 
size of 3.9 kb in human CTX and HL-60 cells 
that most likely corresponds to the dupα7 
transcript (Fig. 6A). This assumption is based on 
two facts: 1) the HL-60 cells appear to express 
only dupα7 transcript (25); and 2) analysis of the 
NCBI EST database provides a theoretical 
prediction of the size of dupα7 mRNA of 3,600 
bp. If we added the about 200 bp corresponding 
to the poly(A+) tail to this value, there is a good 
correlation between the predicted and the 
experimental size of dupα7 mRNA found in the 
present study. The possibility that the 3.9 kb 
band of CTX corresponds to an α7 isoform is 
very remote because we have not been able to 
find any isoform with this size in the literature or 
in NCBI EST database. In fact, the northern blot 
for the CTX mRNA in our study shows 
additional bands which probably correspond to 
several α7 isoforms since their sizes are 
consistent with those found in SHY-5Y cells (47, 
48). Additionally, GeneBank sequence 
NM_000746 gives a size of the transcript 
encoded by the CHRNA7 gene of 3,351 bp, 
which could correspond to the band of 3.3 kb 
identified in our experiments. By identification 
of polysome-bound mRNAs, our results show, 
for the first time, that dupα7 mRNA is being 
translated in HL-60 cells (Fig. 6B), a process 
that has not been demonstrated before because of 
the unavailability of a selective antibody. 
 After demonstrating that dupα7 mRNA is 
translated and that the resulting protein behaves 
as a dominant negative of α7 nAChR activity in 
vitro, it is time to consider whether dupα7 could 
play a relevant functional role in vivo in those 
tissues and cell types that also express α7 
nAChRs, such as the central nervous system (49-
51) where presynaptic α7 nAChRs regulate the 
release of different neurotransmitters (1-4, 52). 
The same can be said of α7 nAChRs in MØ, 
which have an essential role in the cholinergic 
anti-inflammatory response (34, 53-56). 
However, to assume that dupα7 could behave as 
an endogenous modulator for α7 nAChR activity 
in vivo, it is essential that it meet two conditions: 
(i) its mRNA levels must be high enough in 
respect to α7 and/or (ii) the expression levels of 
this messenger should, in turn, be susceptible to 
modulation by external stimuli that require 
greater or lesser α7 activity. 
     When we explored the first condition in 
human CTX and MØ using Q-PCR we found 
that dupα7 mRNA levels in the former tissue 
come to about one-fifth of those of α7 (Fig. 7A). 
This result is consistent with previous data 
obtained in human prefrontal cortex showing 
that expression of α7 mRNA is five times higher 
than that of dupα7 (21). The low proportion of 
dupα7 relative to that of α7 mRNA in CTX is 
functionally relevant in accordance with our data 
from INic recorded in oocytes injected with the 
combination 5:1 of α7:dupα7 mRNA (Fig. 3, A 
and B). 
 A result opposite to that of CTX was 
obtained in MØ, which preferentially express 
dupα7 over the α7 transcript (Fig. 7A). Human 
PBMC and lymphocytes (25, 27, 57), and HL-60 
cells (Fig. 6A) behave similarly. Despite the low 
expression level of α7 mRNA in MØ, there is no 
doubt that it is efficiently translated given the 
high number of functional α7 nAChRs detected 
in our experiments (Fig. 7B) as well as in 
previous studies (34). Thus, the question now is 
why, despite the high level of dupα7 mRNA in 
MØ, α7 nAChR expression is high in these cells. 
At this time we do not have a convincing 
answer, although different efficiencies in 
translation and/or proper folding of the α7 and 
dupα7 proteins could be underlying these 
results. Additional experiments are needed to 
explore these possibilities. 
     In relation to the second condition for 
dupα7’s playing a modulatory role in vivo, our 
results in MØ show that mRNA levels are 
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actually being regulated (Fig. 7C). This is an 
interesting finding since stimulation of α7 
nAChR in macrophages induces a clear anti-
inflammatory response secondary to decreased 
production of pro-inflammatory cytokines (34, 
53, 56, 58). In this context, our results show that 
one of these cytokines, IL-1β, as well as LPS, is 
able to reduce dupα7 mRNA expression by half. 
In these conditions, pro-inflammatory cytokines 
would repress dupα7 expression, and therefore 
increase the number of functional α7 nAChRs; 
the net output of this feedback loop would be the 
attenuation of the inflammatory response. 
Additionally, our finding that nicotine markedly 
reduces the expression levels of dupα7 mRNA 
in MØ (Fig. 7C) are in complete agreement with 
recent in vivo results showing a lower α7 
transcript expression in PBMC from smokers 
than from nonsmokers (57). Further experiments 
are needed to learn whether cerebral dupα7 
mRNA expression can be regulated by different 
stimuli, as occurs in MØ. However, it is 
interesting to note that the ratio of the α7/dupα7 
transcripts varies in different brain regions as 
well as in individuals addicted to drugs or 
suffering certain psychiatric disorders. This is 
the case in schizophrenic patients, who show a 
general decrease in brain α7 mRNA and all 
CHRNA7 transcription products that is most 
marked in the corpus callosum (26). The effect 
of nicotine in reducing dupα7 mRNA levels 
found in our study could explain, at least in part, 
the relief of symptoms experienced by these 
patients after smoking. Also, in bipolar disorder, 
an imbalance in the ratio of 
CHRNA7/CHRFAM7A transcripts due to 
increased expression of dupα7 mRNA has been 
found (21).  
     In summary, our data are consistent with the 
idea that the product resulting from the partial 
duplication of the CHRNA7 gene is likely to be 
modulated in a paracrine and endocrine manner, 
both in physiological as well as pathological 
situations, thereby exerting a negative 
modulating effect on α7 nAChR activity. Thus, 
previous findings regarding the CHRFAM7A and 
its possible association with psychiatric 
disorders can now be interpreted in the light of 
these new results. 
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     FIG. 1. Expression of dupα7 and α7 subunits in GH4C1 cells. A, Confocal images showing the 
fluorescent signal generated in transfected GH4C1 cells stained with the Mab 306 antibody. B, 
Scanned fluorescence intensity along the X-axis in three typical cells of the images above. C, The 
histogram shows pooled results of fluorescence intensity measured in the region of interest (ROI) 
indicated in B.  Each bar represents the mean ± SEM, expressed as a percentage of control (transfected 
with pcDNA3), in the number of cells shown at the top. At least four to six different coverslips from 
two independent cell cultures were used for each experimental condition. Data were analyzed using 
ANOVA and Bonferroni post-hoc tests, where ***p ≤ 0.001 upon comparing transfected versus 
control cells. 
 
     FIG. 2. Confocal images of oocytes expressing dupα7 and α7 subunits. A, Diagram of tertiary 
structures of α7 and dupα7 proteins; the Mab 306 antibody binding region is also indicated. B, Left 
column shows overall confocal (Z-scan) images of three typical intact oocytes (out of 5), non-injected 
(control) or injected with dupα7 or α7 mRNA and immunostained with the antibody. Central and 
right columns show, at a higher magnification, the fluorescent signal at the animal surface in the three 
oocytes.  
 
     FIG. 3. Dupα7 produces a dominant negative effect on α7 currents without affecting receptor 
response to ACh. In all combinations assaying α7:dupα7 mRNAs, the amount of injected α7 mRNA 
(2.5 ng/oocyte) remained constant. A, Original traces of inward nicotine-elicited currents (INic) in six 
oocytes injected with different combinations of α7:dupα7 mRNAs. Each oocyte was voltage-clamped 
at -70 mV and stimulated with repeated pulses of nicotine; the original traces correspond to the time 
when INic becomes stabilized. B, Diagram showing the INic amplitude values for each α7:dupα7 
combination normalized to α7 mRNA-injected oocytes. Each bar shows the mean ± SEM of the 
number of oocytes in parentheses. The data were analyzed using ANOVA and Dunnett post-hoc tests 
to compare all groups with the α7-mRNA injected group; **p ≤ 0.01 and ***p ≤ 0.001. C, Original 
traces of inward currents (IACh) induced by increasing concentrations of ACh applied as succesive 
pulses in one α7 mRNA-injected oocyte; finally, a control pulse of 1 mM ACh to generate a 
maximum current (Imax) was applied. D, Dependence of IACh amplitude, normalized to Imax, on the 
concentation of ACh assayed in oocytes injected with different combinations of α7:dupα7 mRNAs; 
values are mean ± SEM of the number of oocytes shown in parentheses in the table below. The table 
also shows mean ± SEM of EC50 and Hill coefficient values obtained for each combination tested. 
ANOVA analysis showed no significant differences among the four groups of oocytes analyzed.   
 
     FIG. 4. Dupα7 reduces the number of functional α7 nAChRs expressed on the oocyte surface. 
A, Representative confocal images of eight intact oocytes labeled with Mab 306 antibody (top row) or 
FITC-αBgtx (bottom row). Oocytes were injected with α7 (20 ng), dupα7 (20 ng), or with the 
combination (1:1) of α7:dupα7 mRNAs; on the left, two control non-injected oocytes. (Inset) Oocyte 
orientation on the confocal microscope stage; V and A indicate the vegetal and animal hemisphere, 
respectively. B, Histograms show pooled results of fluorescent intensity determined in an ROI located 
on the animal surface of the oocyte; data were normalized in respect to control. Each bar shows the 
mean ± SEM of the number of oocytes in parentheses. The data were analyzed by ANOVA, where *p 
≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 upon comparing injected with control oocytes. #p ≤ 0.05, ###p ≤ 
0.001 after comparing oocytes injected with dupα7 or α7:dupα7 mRNAs versus α7-mRNA injected 
oocytes. C, Saturation curves showing specific binding of [125I]α-Bgtx to the surface of intact oocytes 
injected with α7 mRNA (20 ng) or with the combination α7:dupα7 (20:80 ng). The adjustment of the 
curves and the determination of Kd and Bmax values was done with GraphPad Prism5 sofware. The 
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analysis of the variation in Kd and Bmax between the two groups of oocytes was performed with the 
Mann Whitney test for analysis of two non-parametric variables, * p ≤ 0.05, ** p ≤ 0.01. A total of 6-
8 oocytes from two different donors were used for each value plotted in the curves.  
 
     FIG. 5. The positive allosteric modulator PNU120596, but not 5-hydroxyindole, can 
distinguish among oocytes injected with different combinations of α7:dupα7 mRNAs. The tested 
combinations and the experimental design are shown at the top. The α7 mRNA (2.5 ng/oocyte) 
remains constant in all combinations. Oocytes, voltage-clamped at -70 mV, were stimulated with 
regular pulses of ACh in the absence or presence of the modulator. The effect of 5-hydroxyindole 
(5HI) was evaluated on a single ACh pulse, while in the case of PNU120596 (PNU), the oocyte was 
stimulated with an initial pulse of ACh (0 = control) followed by six successive ACh pulses in the 
presence of the modulator. A, Original traces of ACh-elicited currents (IACh), in the absence or 
presence of 5HI, obtained in two mRNA-injected oocytes. The left and right records correspond to 
one α7-mRNA and one α7:dupα7-mRNA (1:1) injected oocyte, respectively. (Inset) Normalized 
currents of both oocytes. B, Histogram shows the number of times that 5HI increases the control peak 
IACh in each group of oocytes. Each bar shows the mean ± SEM of the number of oocytes in 
parentheses. ANOVA analysis and Dunnett post-hoc tests showed no differences between groups of 
oocytes. C, Original traces showing the PNU effect on IACh over the 1st to 6th pulses of ACh in two 
mRNA-injected oocytes. The left and right records correspond to one α7-mRNA and one α7:dupα7-
mRNA (1:1) injected oocyte, respectively. (Inset) Normalized currents obtained in both oocytes 
corresponding to the initial (control) and the 3rd pulse of ACh in the presence of PNU. D, Graph 
representing the number of times that PNU increased the control peak IACh during the six pulses in 
each group of oocytes. Each point represents the mean ± SEM of 7 oocytes per group. Data were 
analyzed using ANOVA and Bonferroni post-hoc tests, where **p ≤ 0.01, ***p ≤ 0.001 and ## p ≤ 
0.01 after the comparison of the different oocyte groups as indicated.  
 
     FIG. 6. Determination of the size and relative expression levels of dupα7 mRNA in the 
monosomal and polysomal fractions of HL-60 cells. A, Northern blot performed with RNAs from 
human cerebral cortex (CTX) and HL-60 cells showing the 3.9 kb transcript in both lanes and 
different  α7 transcript of 5.8, 3.3, 2.1 and 1.4 kb in CTX. B, Levels of dupα7 or TBP mRNAs in 
monosomal and polysomal fractions of HL-60 cells quantified by Q-PCR. The results are expressed as 
a percentage of each messenger in the two fractions. Values were obtained in triplicate and correspond 
to two different cultures of HL-60 cells subjected to ultracentrifugation on a sucrose gradient as 
described in “Experimental Procedures”.    
 
     FIG. 7. Levels of dupα7 and α7 mRNA in different samples and regulation of dupα7 mRNA 
levels by different treatments. A, Relative expression levels of dupα7 versus α7 mRNA in CTX and 
MØ determined by Q-PCR; values were obtained in triplicate and correspond to a single CTX sample 
and two cultures of MØ from different donors. B, Confocal images of MØ (out of 5) in culture 
immunostained with FITC-αBgtx (left). Cells from the same culture preincubated with a high 
concentration (500 µM) of nicotine (right). C, Effect of different treatments on the expression levels 
of dupα7 mRNA in cultured human MØ. Cells were incubated overnight with IL-1β (25 ng·ml-1), LPS 
(100 ng·ml-1) and nicotine (1 μM) or untreated. The bars show the mean ± SEM of values, obtained in 
triplicate, and quantified by Q-PCR in the number of cultures from different healthy donors shown in 
parentheses. Data were analyzed by ANOVA and Dunnett post-hoc tests; **p ≤ 0.01 with respect to 
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